Novo Nordisk A/S’s Hemophilia Drug, NovoSeven Can Damage Heart, Study Finds

BOSTON, Nov 3 (Reuters) - Using high doses of Novo Nordisk's (NOVOb.CO) anti-clotting medicine to treat dangerous bleeding in non-hemophiliacs may raise the risk of heart attack or related complications, researchers said on Wednesday.